TP53 and cancer: Mifepristone prevented or delayed mammary tumorigenesis in the Brca1/p53-deficient mice [30], produced cancer cellular apoptosis by acting on p53 and B-cell lymphocyte/leukemia-2 (Bcl-2) family proteins [31], and induced a significant time- and dose-dependent cytotoxicity in both human androgen-sensitive LNCaP and androgen-insensitive PC3 and DU145 prostate cancer cell lines [32].